Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the ...

A doctor has revealed six of the biggest mistakes people on weight loss drugs can make. Nobody's perfect, but when it comes ...

Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best strong buy growth stocks to buy now. On August 28, Teva ...

Teva Pharmaceuticals announced in late August 2025 that it received FDA approval and commenced the U.S. launch of its generic version of Saxenda® (liraglutide injection), which had annual sales of ...

Teva Pharmaceuticals gained FDA approval to launch the first generic GLP-1 drug for weight loss, a liraglutide injection based on Saxenda.

The FDA approved the first-ever generic form of a GLP-1 receptor agonist specifically indicated for weight loss, Teva ...

Israeli drugmaker Teva Pharmaceutical Industries has announced US Food and Drug Administration (FDA) approval and launch of a ...

One difference is that liraglutide weight loss injections are injected once daily as opposed to weekly. Saxenda is FDA-approved for weight management in people with obesity.

Victoza and Saxenda injections are currently in shortage and can cost over a thousand dollars each month. Compounding pharmacies can make compounded liraglutide to help address the shortage.

Investing.com -- Teva Pharmaceutical Industries Ltd ADR (NYSE:TEVA) stock rose 2.7% after the company announced FDA approval and U.S. launch of its generic version of Saxenda (liraglutide injection), ...

Comparing weight loss injection options The only FDA-approved injection weight loss drugs are Wegovy, Saxenda and Zepbound.